Old Web
English
Sign In
Acemap
>
Paper
>
PO-1013: A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC.
PO-1013: A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC.
2020
Cedric M. Panje
Judith E. Lupatsch
M. Barbier
E. Pardo
M. Lorez
Konstantin J. Dedes
Daniel M. Aebersold
Ludwig Plasswilm
O. Gautschi
Matthias Schwenkglenks
Keywords:
Immunotherapy
Oncology
Medicine
Durvalumab
Cost-effectiveness analysis
Stage III NSCLC
Consolidation (soil)
Internal medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]